ASCO 2018 - Tarceva or Tarceva with Avastin as 1st Line for EGFR Pos. NSCLC vs. Tagrisso or Vizimpro
Author: cancergrace
Added: 06/26/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2019 Category: Cancer & Oncology Source Type: podcasts
The Erlotinib/Bevacizumab Combination in EGFR Mutation-Positive Advanced NSCLC: Is Progression-Free Survival without Overall Survival Benefit Enough? (BMIC-043)
Dr. Jack West discusses results and the significance of two important Japanese trials that test the combination of erlotinib (Tarceva) with bevacizumab (Avastin), which shows a consistent improvement ...
Author: BeaconMedIC
Added: 07/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2018 Category: Cancer & Oncology Source Type: podcasts
Osimertinib Versus Erlotinib or Gefitinib in The FLAURA Trial
Joshua Bauml, MD of the University of Pennsylvania discusses Osimertinib v Erlotinib or Gefitinib in the FLAURA Trial from the 22nd Annual Perspectives in Thoracic Oncology in New York <a target='_blank' href='http://imedex.c'>http://imedex.c...</a>...
Author: thoraciconcology
Added: 12/28/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 28, 2017 Category: Cancer & Oncology Source Type: podcasts
The FLAURA Trial: Practice-Changing Results for Patients with EGFR Mutation-Positive NSCLC (BMIC-007)
Dr. Jack West summarizes the likely practice-changing results of the FLAURA trial of osimertinib vs. standard of care EGFR TKI therapy (gefitinib or erlotinib) as first line treatment for patients wit...
Author: BeaconMedIC
Added: 09/10/2017 (Source: Oncology Tube)
Source: Oncology Tube - September 11, 2017 Category: Cancer & Oncology Source Type: podcasts
Early Returns on the FLAURA Trial: Should Osimertinib be a First Line Agent in EGFR Mutation-Positive NSCLC? (BMIC-002)
Dr. Jack West discusses the implications of a positive FLAURA trial, which revealed a significant improvement in progression-free survival for first line osimertinib over gefitinib or erlotinib in pat...
Author: BeaconMedIC
Added: 08/29/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 30, 2017 Category: Cancer & Oncology Source Type: podcasts
How, when, and where to utilize erlotinib, afatinib, and gefitinib in EGFR positive NSCLC
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vera Hirsh discusses how, when, and where to utilize erlotinib, afatinib, and gefitinib in EGFR-positive non-small cell...
Author: imedex
Added: 05/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 5, 2017 Category: Cancer & Oncology Source Type: podcasts
Atezolizumab with erlotinib in combination treatment for EGFR mutant NSCLC
Charles Rudin MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY discusses targeted therapies, immunotherapy and their combination in non-small cell lung cancer (NSCLC) therapy. Targe...
Author: VJOncology
Added: 02/14/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 14, 2017 Category: Cancer & Oncology Source Type: podcasts
Chemoradiotherapy vs Chemotherapy for Pancreatic Cancer
Interview with Pascal Hammel, MD, author of
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients
With Locally Advanced Pancreatic Cancer Controlled After 4 Months
of Gemcitabine With or Without Erlotinib: The LAP07 Randomized
Clinical Trial (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - May 3, 2016 Category: Journals (General) Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
Chemoradiotherapy vs Chemotherapy on for Pancreatic Cancer
Interview with Pascal Hammel, MD, author of
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients
With Locally Advanced Pancreatic Cancer Controlled After 4 Months
of Gemcitabine With or Without Erlotinib: The LAP07 Randomized
Clinical Trial (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - May 3, 2016 Category: Journals (General) Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?
Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Ta...
Author: cancergrace
Added: 12/09/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 9, 2015 Category: Cancer & Oncology Source Type: podcasts
BELIEF: Phase 2 trial of erlotinib and bevacizumab in non-small cell lung cancer | Dr Bartomeu Massuti at ECC 2015
At the European Cancer Congress (ECC) 2015, Bartomeu Massuti, MD, of Hospital General de Alicante, Alicante, Spain, discusses the Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Pl...
Author: EMJ
Added: 11/16/2015 (Source: Oncology Tube)
Source: Oncology Tube - November 16, 2015 Category: Cancer & Oncology Source Type: podcasts
JAMA Oncology : Erlotinib and the Risk of Oral Cancer
Interview with William N. William Jr, MD, and Scott M. Lippman, MD, author of Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - November 5, 2015 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
Erlotinib and the Risk of Oral Cancer (JAMA Oncology)
Interview with William N. William Jr, MD, and Scott M. Lippman, MD, author of Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - November 5, 2015 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
Ask the Lung Cancer Expert: Your Questions Answered by Dr. Paul Paik
Dr. Paul Paik, lung cancer expert and medical oncologist at Memorial Sloan Kettering Cancer Center, answers questions submitted by patients. Several subjects are covered and include erlotinib (Tarceva...
Author: patientpower
Added: 11/03/2015 (Source: Oncology Tube)
Source: Oncology Tube - November 4, 2015 Category: Cancer & Oncology Source Type: podcasts
Should Avastin be Added to EGFR TKI Therapy for EGFR Mutation-Positive NSCLC?
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mut...
Author: cancergrace
Added: 10/07/2015 (Source: Oncology Tube)
Source: Oncology Tube - October 7, 2015 Category: Cancer & Oncology Source Type: podcasts
